Genetic Testing for Prostate Cancer - Advances and Considerations

Explore the latest advances in genetic testing for prostate cancer in this informative webinar presented by Ambry Genetics. Gain insights into the growing importance of germline testing in cancer care, its role in predicting prostate cancer risk, and its relevance for precision therapies. Learn about the genetic contribution to prostate cancer risk, principles of genetic counseling, and guidance on implementing germline prostate cancer testing based on the 2019 Philadelphia Prostate Cancer Consensus Conference. Delve into topics such as prostate gland anatomy, screening tests, biopsy procedures, Gleason scores, staging, therapies including PARP inhibitors, FDA approvals, active surveillance, polygenic risk scores, and common prostate cancer genes. Understand the challenges in genetic testing implementation and discover practical guidelines for integrating genetic evaluation into prostate cancer care. This comprehensive presentation, delivered by expert Dr. Veda Giri, offers valuable knowledge for healthcare professionals and researchers involved in prostate cancer management and genetic risk assessment.

Intro
Disclosures
Objectives
Prostate Gland Anatomy
Screening Tests
Prostate Biopsy
Gleason Score
Stage
Therapy
PARP Inhibitors
FDA Approvals
Olaparib
Pembrolizumab
Active Surveillance
Prostate Cancer Screening
Polygenic Risk Scores
Genetic Counseling
Genomic Testing
Clinical Uses
Common Prostate Cancer Genes
Challenges
Philadelphia Consensus Conference
Implementation Model
Guidelines
Summary
Questions